Literature DB >> 11285124

Activation of cell-mediated immunity following immunization with pneumococcal conjugate or polysaccharide vaccine.

T Wuorimaa1, H Käyhty, J Eskola, A Bloigu, O Leroy, H M Surcel.   

Abstract

The immunogenicity of pneumococcal polysaccharide (PS) vaccines can be improved by conjugating PS to a polypeptide carrier that alters the immune response from T-cell independent to T-cell dependent. In order to study the influence of PS or protein antigens as inducers of cell-mediated responses, 30 adults were immunized with a 23-valent pneumococcal PS vaccine (PS-group) or an 11-valent, tetanus and diphtheria mixed carrier conjugate vaccine with (adjuvant group) or without aluminium adjuvant (nonadjuvant group). Cell-mediated responses were analyzed on days 0, 14 and 28 after vaccination by measuring lymphocyte proliferation and production of interferon (IFN)-gamma (Th1 marker) or interleukin (IL)-4 and IL-5 (Th2 markers) cytokines after in vitro stimulation with the PS and protein components of the vaccines. Tetanus and diphtheria proteins were the main inducers of lymphocyte proliferative and cytokine responses. Conjugate vaccines induced increased proliferative responses to the tetanus or diphtheria protein, but not to the PS components. In the PS-group, a lymphocyte proliferative response to protein antigens was not observed. The number of antigen-specific and nonspecific IFN-gamma-secreting cells detected by ELISPOT tended to increase in all three groups in response to protein or to PS antigen. No major differences were detected in the number of IL-4-secreting cells measured 14 and 28 days after vaccination. The conjugate vaccine with adjuvant was associated with Th2 type of activation indicated by an enhanced IL-5 secretion in response to the tetanus and diphtheria protein antigens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11285124     DOI: 10.1046/j.1365-3083.2001.00882.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  10 in total

1.  Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine.

Authors:  A W Zuercher; M A Imboden; S Jampen; D Bosse; M Ulrich; H Chtioui; B H Lauterburg; A B Lang
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

2.  Anti-Pneumococcal Vaccine-Induced Cellular Immune Responses in Post-Traumatic Splenectomized Individuals.

Authors:  Djursun Karasartova; Umut Gazi; Ozgur Tosun; Ayse S Gureser; Ibrahim T Sahiner; Mete Dolapci; Aysegul T Ozkan
Journal:  J Clin Immunol       Date:  2017-05-09       Impact factor: 8.317

3.  Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.

Authors:  F M Russell; J R Carapetis; A Balloch; P V Licciardi; A W J Jenney; L Tikoduadua; L Waqatakirewa; J Pryor; J Nelson; G B Byrnes; Y B Cheung; M L K Tang; E K Mulholland
Journal:  Vaccine       Date:  2010-03-04       Impact factor: 3.641

4.  Immunomodulatory effects of maternal atrazine exposure on male Balb/c mice.

Authors:  Alexander M Rowe; Kathleen M Brundage; Rosana Schafer; John B Barnett
Journal:  Toxicol Appl Pharmacol       Date:  2006-01-27       Impact factor: 4.219

5.  Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine.

Authors:  A W Zuercher; M A Imboden; S Jampen; D Bosse; M Ulrich; H Chtioui; B H Lauterburg; A B Lang
Journal:  Clin Exp Immunol       Date:  2005-11       Impact factor: 4.330

6.  Neutrophils Are Required During Immunization With the Pneumococcal Conjugate Vaccine for Protective Antibody Responses and Host Defense Against Infection.

Authors:  Essi Y I Tchalla; Manmeet Bhalla; Elizabeth A Wohlfert; Elsa N Bou Ghanem
Journal:  J Infect Dis       Date:  2020-09-14       Impact factor: 5.226

7.  Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac.

Authors:  Paul A Kristiansen; Absatou Ky Ba; Abdoul-Salam Ouédraogo; Idrissa Sanou; Rasmata Ouédraogo; Lassana Sangaré; Fabien Diomandé; Denis Kandolo; Inger Marie Saga; Lara Misegades; Thomas A Clark; Marie-Pierre Préziosi; Dominique A Caugant
Journal:  BMC Infect Dis       Date:  2014-12-04       Impact factor: 3.090

8.  Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients.

Authors:  Anja Gäckler; Nils Mülling; Kim Völk; Benjamin Wilde; Ute Eisenberger; Hana Rohn; Peter A Horn; Oliver Witzke; Monika Lindemann
Journal:  Vaccines (Basel)       Date:  2021-12-06

9.  Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED.

Authors:  Andrea Vambutas; James DeVoti; Elliot Goldofsky; Michael Gordon; Martin Lesser; Vincent Bonagura
Journal:  PLoS One       Date:  2009-04-29       Impact factor: 3.240

10.  Elicitation of integrated immunity in mice by a novel pneumococcal polysaccharide vaccine conjugated with HBV surface antigen.

Authors:  Wen Qian; Zhen Huang; Yuqiu Chen; Jinling Yang; Lili Wang; Kai Wu; Min Chen; Nanping Chen; Yongzhong Duan; Jing Shi; Ying Zhang; Qihan Li
Journal:  Sci Rep       Date:  2020-04-14       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.